Evenity(romosozumab)
Evenity (romosozumab) is an antibody pharmaceutical. Romosozumab was first approved as Evenity on 2019-04-09. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis. The pharmaceutical is active against sclerostin.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| musculoskeletal diseases | D009140 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Evenity
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| evenity | Biologic Licensing Application | 2025-04-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| postmenopausal osteoporosis | EFO_0003854 | D015663 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J3111 | Injection, romosozumab-aqqg, 1 mg |
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 3 | 4 | 7 | 10 | 2 | 26 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | 3 | 5 | 5 | 2 | 15 |
| Metabolic bone diseases | D001851 | — | — | 4 | 2 | 2 | 1 | — | 9 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | 2 | — | 2 | — | 4 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | 2 | — | 1 | — | 3 |
| Osteoporotic fractures | D058866 | — | — | — | — | — | 2 | — | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bone diseases | D001847 | — | M89.9 | — | 1 | 1 | — | — | 2 |
| Osteogenesis imperfecta | D010013 | — | Q78.0 | 1 | — | 1 | — | — | 2 |
| Musculoskeletal diseases | D009140 | — | — | — | — | 1 | — | — | 1 |
| Anorexia | D000855 | — | R63.0 | — | — | 1 | — | — | 1 |
| Feeding and eating disorders | D001068 | — | F50 | — | — | 1 | — | — | 1 |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fracture healing | D017102 | — | — | — | 2 | — | — | — | 2 |
| Spinal cord diseases | D013118 | — | G95.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Postmenopause | D017698 | — | — | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Romosozumab |
| INN | romosozumab |
| Description | Romosozumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107874 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11866 |
| UNII ID | 3VHF2ZD92J (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Evenity – Amgen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,714 documents
View more details
Safety
Black-box Warning
Black-box warning for: Evenity
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,621 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use